- Home
- SORA vs CRDF Comparison
SORA vs CRDF Comparison
Compare SORA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | CRDF |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.0M | 142.1M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SORA | CRDF |
|---|---|---|
| Price | $3.17 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 9.5K | ★ 1.1M |
| Earning Date | 05-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,081,504.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $1.90 |
| 52 Week High | $14.15 | $4.99 |
Technical Indicators
Market Signals| Indicator | SORA | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.44 |
| Support Level | N/A | $2.32 |
| Resistance Level | N/A | $3.31 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 34.05 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.